-
公开(公告)号：EP4413144A1
公开(公告)日：2024-08-14
申请号：EP22878062.3
申请日：2022-10-07
发明人： GEALL, Andy John , ABRAHAM, Suraj , THOMAS, Anitha , THAMPATTY, Sitalakshmi Radhakrishnan , CHEMMANNUR, Sijo
IPC分类号： C12N15/85 , A61K9/51 , A61K39/215 , A61P31/14 , A61P37/04 , C07K14/165 , C12N15/50 , C12N15/88 , C12N15/113
-
公开(公告)号：EP4333884A1
公开(公告)日：2024-03-13
申请号：EP22798476.2
申请日：2022-05-05
发明人： JEFFERIES, Wilfred , RIBECA, Paolo
IPC分类号： A61K39/12 , A61K9/51 , A61K39/00 , A61K39/215 , A61P31/00 , A61P31/14 , A61P37/04 , C07K14/005 , C07K14/165 , C12N7/00 , C12N15/50
-
公开(公告)号：EP4314022A1
公开(公告)日：2024-02-07
申请号：EP22715657.7
申请日：2022-03-25
申请人： IOSBIO LTD
发明人： DREW, Jeffrey
IPC分类号： C07K14/165 , C12N15/50 , A61K39/215 , C12N15/861 , C12N7/00
-
公开(公告)号：EP4286510A1
公开(公告)日：2023-12-06
申请号：EP22745867.6
申请日：2022-01-25
发明人： SHIRAKAWA, Toshiro , UENO, Shunpei , KITAGAWA, Koichi , KONDO, Akihiko , KAMEOKA, Masanori , KATAYAMA, Takane
IPC分类号： C12N1/21 , A61K35/745 , A61K39/215 , A61P31/14 , A61P37/04 , C07K14/165 , C07K14/195 , C07K19/00 , C12N15/31 , C12N15/50 , C12N15/62
摘要： Provided is an orally administrable vaccine against a coronavirus infectious disease. A transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium enables the provision of the orally administrable vaccine against a coronavirus infectious disease. The transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium can induce humoral immunity and cellular immunity through oral administration to suppress an increase in severity of pneumonia or the like even after viral infection.
-
公开(公告)号：EP4206217A1
公开(公告)日：2023-07-05
申请号：EP21858402.7
申请日：2021-08-20
申请人： RIKEN
发明人： FUJII, Shinichiro , SHIMIZU, Kanako
IPC分类号： C07K14/165 , A61K38/08 , A61K38/10 , A61K39/215 , A61P31/14 , C07K7/06 , C07K7/08 , C12N15/50
摘要： This disclosure relates to a peptide inducing immunity to SARS-CoV-2. Also, the disclosure relates to a composition containing the peptide and inducing immunity to SARS-CoV-2.
-
6.发明公开
公开(公告)号：EP4196582A1
公开(公告)日：2023-06-21
申请号：EP21856737.8
申请日：2021-08-12
IPC分类号： C12N15/11 , C12N15/50 , C12Q1/6809 , G06F17/16 , G06F17/40
-
公开(公告)号：EP4166158A1
公开(公告)日：2023-04-19
申请号：EP21821552.3
申请日：2021-06-10
发明人： KAWAOKA, Yoshihiro , IMAI, Masaki , YAMAYOSHI, Seiya , ISHII, Ken , KOBIYAMA, Kouji , NAMBA, Eiko , OKA, Tatsuya , TOZUKA, Miyuki , JONAI, Nao , ONODERA, Yoshikuni , TAKESHITA, Fumihiko , SUZUKI, Takashi , NIWA, Takako , KOIZUMI, Makoto , NAKAMURA, Kensuke
IPC分类号： A61K39/00 , A61K39/215 , A61K48/00 , A61P31/12 , A61P31/14 , C07K14/165 , A61K9/107 , A61K9/14 , A61K47/14 , A61K47/18 , A61K47/24 , A61K47/28 , C12N15/50 , C12N15/88 , A61K31/7105
摘要： The present invention provides a vaccine for preventing and/or treating infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the S protein and/or a fragment thereof of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof
wherein R 1 and R 2 each independently represent a C 1 -C 3 alkyl group;
L 1 represents a C 17 -C 19 alkenyl group which may have one or a plurality of C 2 -C 4 alkanoyloxy groups;
L 2 represents a C 10 -C 19 alkyl group which may have one or a plurality of C 2 -C 4 alkanoyloxy groups or a C 10 -C 19 alkenyl group which may have one or a plurality of C 2 -C 4 alkanoyloxy groups; and
p is 3 or 4.-
公开(公告)号：EP4155406A1
公开(公告)日：2023-03-29
申请号：EP21807863.2
申请日：2021-05-14
发明人： ZHU, Tao , WANG, Haomeng , LI, Jin , YAN, Qiaoling , SHEN, Chunlin , SHAO, Zhongqi , LI, Junqiang , YU, Xuefeng , CHAO, Shoubai
IPC分类号： C12N15/50 , C07K14/165 , A61K39/215 , A61P31/14
摘要： Provided are an mRNA or an mRNA composition, and an mRNA vaccine comprising the mRNA or the mRNA composition. The mRNA or the mRNA composition comprises an mRNA sequence encoding an S protein of a novel coronavirus SARS-CoV-2 or a variant thereof, and an mRNA sequence encoding an RBD in the S protein or a variant thereof. Further provided are the applications of the mRNA or the mRNA composition, and the mRNA vaccine comprising the mRNA or the mRNA composition in preparation of a medication for preventing and/or treating a disease caused by a novel coronavirus SARS-CoV-2 infection.
-
公开(公告)号：EP4116438A1
公开(公告)日：2023-01-11
申请号：EP21764817.9
申请日：2021-03-03
发明人： YOKONO Kota , YAMAMOTO Machiko , YUKI Syota , FUKAYA Ai , KUBOTA Yutaka
IPC分类号： C12Q1/6888 , C12N15/09 , C12N15/50 , C12Q1/6844 , C12Q1/70
摘要： Disclosed are oligonucleotide primers that hybridize specifically with any base sequence designed from the base sequences of the N gene, RNA-dependent RNA polymerase gene, M gene, and S gene of SARS-CoV-2, a nucleic acid amplification method using said primers, a test method for SARS-CoV-2 infection by detection of nucleic acid amplification, and a COVID-19 test kit.
-
公开(公告)号：EP4103192A1
公开(公告)日：2022-12-21
申请号：EP21754076.4
申请日：2021-02-12
申请人： Cytoagents, Inc.
发明人： CRAIGO, Jodi
IPC分类号： A61K31/5575 , C12N15/50 , A61P11/00 , A61P31/14 , A61P37/02
-
-
-
-
-
-
-
-
-
搜索结果
133 条记录 (耗时 0.017 秒)
